Zum Hauptinhalt springen

Amyloidose

Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:

Definition:
Gruppe von Erkrankungen, bei der es durch extrazelluläre Ablagerung von unlöslichen Proteinkomplexen (Amyloid) zu Organfunktionseinschränkungen kommt.
Häufigkeit: 
In Europa Inzidenz etwa 1:100.000, häufigste Form AL-Amyloidose.
Symptome:
Abhängig von Organbefall.
Befunde:
Organomegalie, Proteinurie, Herzinsuffizienz, Neuropathie, Malabsorption.
Diagnostik:
Biopsie zur Diagnosesicherung und Typisierung der abgelagerten Proteine.
Therapie:
Abhängig von Subtyp, meistens palliativ.
  1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898-909. New England Journal of Medicine  
  2. D'Aguanno V, Ralli M, Artico M, et al. Systemic Amyloidosis: a Contemporary Overview. Clin Rev Allergy Immunol 2019. www.ncbi.nlm.nih.gov  
  3. Nienhuis HLA, Bijzet J, Hazenberg BPC. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel) 2016; 2(1): 10-19. www.ncbi.nlm.nih.gov  
  4. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016; 387(1038): 2641-2654. www.ncbi.nlm.nih.gov  
  5. Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med 2007; 356: 2413-5. PubMed  
  6. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013; 161(4): 525-32. www.ncbi.nlm.nih.gov  
  7. Westermark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid 2011; 18:175. PubMed  
  8. Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21(4): 221-4. www.ncbi.nlm.nih.gov  
  9. Gillmore JD1, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 2015; 168(2): 207-18. www.ncbi.nlm.nih.gov  
  10. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79(4): 319-28. www.ncbi.nlm.nih.gov  
  11. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012; 101(10): 805-13. www.ncbi.nlm.nih.gov  
  12. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369(9): 819-29. www.ncbi.nlm.nih.gov  
  13. Gatt ME, Palladini G. Light chain amyloidosis 2012: a new era. Br J Haematol 2013; 160(5): 582-98. www.ncbi.nlm.nih.gov  
  14. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.. Ann Intern Med 2004; 140(2): 85-92. www.ncbi.nlm.nih.gov  
  15. Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. Br J Haematol 2016; 172(2): 170-86. www.ncbi.nlm.nih.gov  
  16. Nakamura T, Higashi S, Tomoda K, et al. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.. Clin Rheumatol 2010; 29(12): 1395-401. www.ncbi.nlm.nih.gov  
  17. Pettersson T, Kantonen J, Matikainen S, et al. Setting up TRAPS. Ann Med 2012; 44(2): 109-18. www.ncbi.nlm.nih.gov  
  18. Lane T, Loeffler JM, Rowczenio DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 2013; 65(4): 1116-21. www.ncbi.nlm.nih.gov  
  19. Ericzon BG, Wilczek HE, Larsson M, et al. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?. Transplantation 2015; 99(9): 1846-54. www.ncbi.nlm.nih.gov  
  20. Janssen S, Van Rijswijk MH, Meijer S, et al. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986; 29(11): 376-85. www.ncbi.nlm.nih.gov  
  21. Hemminki K, Li X, Försti A, Sundquist J, et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health 2012; 12: 974. www.ncbi.nlm.nih.gov  
  22. Gillmore JD1, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358(9275): 24-9. www.ncbi.nlm.nih.gov  
  • Lino Witte, Dr. med., Arzt in Weiterbildung, Innere Medizin, Frankfurt
  • Bjørnar Grenne, PhD, konst. overlege, Klinikk for hjertemedisin, St. Olavs Hospital, Trondheim
  • Gunnar Husby, professor i revmatologi ved Universitetet i Oslo og Revmatologisk avdeling, Rikshospitalet, Oslo